^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
New
Title:

NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma

Excerpt:
Patient 46 did not tolerate gemcitabine and nab-paclitaxel and came off treatment after 1 cycle….He initiated treatment with afatinib at a dose of 30 mg daily. After 4 weeks, a repeat PET/CT was performed also showing significant response to therapy (Fig. 3B, right)....Response was confirmed by CT imaging performed after 8 weeks following treatment initiation, and a CT scan done 5 months after treatment initiation showed ongoing response.
DOI:
10.1158/1078-0432.CCR-19-0191